Chronic activation of IKKβ/NF‑κB in the mediobasal hypothalamus suppresses GnRH release by up to 50 % through c‑Fos/c‑Jun and PKC signaling [IKKβ/NF‑κB suppresses GnRH]. This decline impairs adult neurogenesis throughout the brain, a mechanism that rescues cognitive and muscular aging when GnRH is restored [GnRH restores neurogenesis]. Yet no study has examined whether this hypothalamic‑GnRH‑neurogenesis cascade directly shapes nociceptive processing. We hypothesize that reduced GnRH signaling diminishes neurogenesis in key descending pain modulatory regions—the periaqueductal gray (PAG), anterior cingulate cortex (ACC), and insular cortex—thereby weakening endogenous opioid and GABAergic inhibition and lowering pain tolerance. Consequently, individual differences in pain sensitivity reflect the functional state of hypothalamic IKKβ/NF‑κB activity and serve as a behavioral read‑out of biological age that may outperform molecular clocks.

Mechanistically, GnRH receptors are expressed on neural progenitor cells in the PAG and ACC, where they promote proliferation and differentiation via MAPK/ERK pathways [GnRH receptors in limbic regions]. Loss of GnRH signaling reduces DCX⁺ and BrdU⁺ cell counts, impairing circuit plasticity. Younger animals with intact hypothalamic GnRH show robust PAG‑mediated analgesia; experimentally inducing IKKβ/NF‑κB in the hypothalamus (via AAV‑IKKβ‑CA) should decrease GnRH, reduce neurogenesis in PAG/ACC/insula, and produce measurable hyperalgesia in hot‑plate and von Frey tests without peripheral injury. Restoring GnRH pulsatile delivery (via pump or GnRH agonist) should rescue neurogenesis and normalize pain thresholds, confirming causality.

Testable predictions:

1. Hypothalamus‑specific IKKβ/NF‑κB activation lowers circulating and cerebrospinal fluid GnRH by ~40‑60 % (ELISA).
2. Corresponding regions show a 30‑50 % drop in neurogenesis markers (immunohistochemistry for DCX, Sox2) after 4 weeks.
3. Pain latency on the hot‑plate test declines by ~25 % and mechanical thresholds drop by ~20 % compared with controls.
4. Chronic GnRH replacement restores neurogenesis to ≥80 % of baseline and reverses hyperalgesia.
5. Across a cohort of aged mice, individual pain tolerance scores correlate inversely with hypothalamic p‑IKKβ levels (r < ‑0.6) and directly with PAG neurogenesis density (r > 0.5), outperforming epigenetic age predictors in regression models.

Falsification occurs if hypothalamic IKKβ/NF‑κB manipulation alters GnRH without affecting neurogenesis or pain behavior, or if GnRH restoration fails to rescue either phenotype despite confirmed receptor engagement. This framework links central inflammatory aging to subjective pain experience, offering a rapid, noninvasive proxy for biological age that bridges neuroendocrine, neurogenic, and sensory systems.